DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eccogene - 1 Wegovy - 1 Eli Lilly - 1 Lilly - 1 It's - 1 Colin White - 1 James Gordon - 1 Morgan Stanley - 1
Top related locs:
U.S Canary Wharf London Britain
Top related orgs:
JPMorgan - 2 AstraZeneca - 1 Novo Nordisk - 1 Food and Drug Administration - 1 Centers for Disease Control - 1 UBS - 1 Wall Street - 1 London Stock Exchange - 1

Search resuls for: "JPMorgan Cazenove"


3 mentions found


☆ There's a new entry into the weight loss drug boom. Here's the outlook for the stock
  + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +3 min
AstraZeneca is the latest player to enter the weight loss drug arena, a market which some analysts have forecasted could reach $100 billion by 2030 . The GLP-1 drug market is currently dominated by two players: Novo Nordisk , which sells Type 2 diabetes treatment Ozempic and weight loss medication Wegovy, and Eli Lilly , which sells Mounjaro as a treatment for Type 2 diabetes. Lilly just had the weight loss version of its drug, Zepbound , approved by the Food and Drug Administration. It's still early days for AstraZeneca's ECC5004 drug, which is being assessed in a U.S.-based phase 1 trial involving patients with Type 2 diabetes. He currently rates AstraZeneca stock as overweight.
Persons: Eccogene, Wegovy, Eli Lilly, Lilly, It's, Colin White, James Gordon, Morgan Stanley, Mark Purcell, AstraZeneca's Farxiga, Purcell, Michael Bloom, Christina Cheddar, Berk Organizations: AstraZeneca, Novo Nordisk, Food and Drug Administration, Centers for Disease Control, UBS, Wall Street, JPMorgan Locations: U.S
☆ LSEG says on track to meet 2023 growth targets
  + stars: | 2023-10-19 | by ( Huw Jones | ) www.reuters.com   time to read: +2 min
Signage for the London Stock Exchange Group is seen outside of offices in Canary Wharf in London, Britain, August 3, 2023. “LSEG delivered another quarter of strong, broad-based growth," LSEG Chief Executive David Schwimmer said in a statement, adding that he was confident that total income growth for the full year will be towards the upper end of a guidance range of 6% to 8%. Data and analytics, which now make up the bulk of LSEG income, was up 7.2% year on year at 1.29 billion pounds ($1.57 billion) on improving sales, rising retention of existing customers and a higher annual price increase, LSEG said. Organic ASV growth remains broadly around the level seen in the first and second quarters, LSEG said, adding that all 2023 guidance is reiterated, including EBITDA margin and capital expenditure. JPMorgan Cazenove analysts said third-quarter gross profit was in line with company-compiled consensus, but "most importantly" organic ASV growth recovered after dipping to 6.9% in the second quarter.
Persons: Toby Melville, “ LSEG, David Schwimmer, LSEG, JPMorgan Cazenove, Huw Jones, Mark Potter, Sinead Cruise Organizations: London Stock Exchange, REUTERS, JPMorgan, ASV, RBC, Microsoft, Thomson Locations: Canary Wharf, London, Britain
☆ Revisiting JPMorgan’s innovative Cazenove deal
  + stars: | 2023-02-24 | by ( Peter Thal Larsen | ) www.reuters.com   time to read: +6 min
JPMorgan avoided most of these problems by structuring its deal as a joint venture with Cazenove. Though the corporate entity called JPMorgan Cazenove was quietly wound down a few years ago, the name still graces the U.S. group’s UK banking business. At the time of the JPMorgan deal, Cazenove acted as broker to almost half of the companies in the FTSE 100 Index (.FTSE). By 2009, the enlarged business reported a pre-tax profit of 280 million pounds. The Cazenove deal still stands as a case study of how to buy an investment bank without destroying it.
0 next >>
Total: 3